Professor Jacob P. Thyssen - Using Biologics to Manage Moderate to Severe Atopic Dermatitis: Compare Your Approach With Experts From Around the World

Go online to PeerView.com/RBZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis is a chronically relapsing skin disease that often begins in early childhood and can persist into adulthood, having a detrimental effect on the lives of patients and their families throughout the lifespan. In this activity, based on a recent live web broadcast, our global experts provide both pediatric and adult dermatologists, allergy/immunology specialists, and other specialty advanced practice providers around the world greater insight into the assessment of disease severity, the use of targeted biologic therapy, and the importance of patient engagement and shared decision-making in the management of atopic dermatitis. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD); Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines; Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would likely benefit from targeted therapy; Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of AD and engage them in their care